503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Open-Data Consumer Watchdog

GLP-1 Telehealth Comparisons & 2026 Fee Teardowns

Our independent GLP-1 telehealth comparisons audit hidden membership fees, dose-escalation upcharges, and contract lock-ins across major online clinics against Losing Weight RX's $49/mo flat rate. Side-by-side 52-week total expenditure teardowns backed by DOI 10.5281/zenodo.24139315.

52-Week Competitor Audit · $5,173 vs $637

Ro Body vs. Losing Weight RX

Charges $1,740/year in recurring platform membership dues that include $0 of medication.

52-Week Competitor Audit · $3,347 vs $637

WeightRx vs. Losing Weight RX

Advertised lowest rates require non-refundable 12-month upfront contract commitments plus high-dose step increases.

52-Week Competitor Audit · $14,196 vs $637

Sequence (WW Clinic) vs. Losing Weight RX

Subscription covers prior-authorization paperwork only; uninsured or denied patients still face $990–$1,060 retail medication bills.

52-Week Competitor Audit · $5,356 vs $637

Found Health vs. Losing Weight RX

Combines a recurring coaching/platform membership fee with higher monthly charges at therapeutic GLP-1 doses.

52-Week Competitor Audit · $4,761 vs $637

Henry Meds vs. Losing Weight RX

Adds $100/month extra once patients titrate past 1.0 mg/wk semaglutide or 10 mg/wk tirzepatide.

52-Week Competitor Audit · $3,366 vs $637

Ivim Health vs. Losing Weight RX

Requires an active $75/month ($900/year) membership fee on top of every compounded medication refill.

52-Week Competitor Audit · $13,259 vs $637

PlushCare vs. Losing Weight RX

Bills per-visit physician consult fees plus monthly membership without bundling affordable flat-rate 503A medication.

52-Week Competitor Audit · $5,422 vs $637

LifeMD Weight Management vs. Losing Weight RX

Locks patients into multi-month virtual care memberships billed separately from pharmacy fulfillment.

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in GLP-1 Telehealth Comparisons & 2026 Fee Teardowns is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 178(11), 1549-1560. https://doi.org/10.7326/ANNALS-24-03609
  2. Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025). Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA health forum, 6(3), e245586. https://doi.org/10.1001/jamahealthforum.2024.5586
  3. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  4. U.S. Food and Drug Administration. (2025). FDA drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580